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Abstract
Background: Innate immunity including macrophages (Mϕ) in lupus nephritis (LN) has been gaining attention, but
roles of Mϕ in LN remain uncertain.
Methods: Immunohistochemical staining was performed to determine CD68, CD163, heme oxygenase (HO)-1
(a stress-inducible heme-degrading enzyme with anti-inflammatory property), pSTAT1, and CMAF-expressing Mϕ in
the glomeruli of patients with LN. Effects of type I interferons on the expression levels of CD163, HO-1, BTB and
CNC homology 1 (Bach1; a transcriptional HO-1 repressor), interleukin (IL)-6, and IL-10 by human M2-like Mϕ, which
were differentiated in vitro from peripheral monocytes with macrophage colony-stimulating factor, were assessed
by RT-PCR and immunocytostaining. Clinical manifestations, anti-double-stranded DNA (anti-dsDNA), and local HO-1
expression were compared in Bach1-deficient and wild-type MRL/lpr mice.
Results: The number of glomerular M2-like Mϕ correlated with the amounts of proteinuria in patients with LN.
Unlike monocyte-derived M2-like Mϕ, HO-1 expression was defective in the majority of glomerular M2-like Mϕ of
patients with LN. Stimulation of human M2-like Mϕ with type I interferons led to reduced HO-1 expression and
increased Bach1 and IL-6 expression. Bach1-deficient MRL/lpr mice exhibited increased HO-1 expression in kidneys,
prolonged survival, reduced urine proteins, and serum blood urea nitrogen levels, but serum anti-dsDNA antibody
levels were comparable. Increased expression of CD163 and HO-1 was found in peritoneal Mϕ from Bach1-deficient
MRL/lpr mice.
Conclusions: Our data suggest that dysregulated M2-like Mϕ play a proinflammatory role in LN. Bach1 is a
potential therapeutic target that could restore the anti-inflammatory property of M2 Mϕ.
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Background
Systemic lupus erythematosus (SLE) is an autoimmune
disease with a broad spectrum of clinical presentations
[1]. Lupus nephritis (LN) occurs in approximately 25–50%
of patients with SLE and remains one of the leading causes
of morbidity [2]. New immunosuppressive therapies such
as mycophenolate mofetil have been improving disease
outcomes in patients with SLE, but some patients are re-
fractory to standard treatments [3, 4]. Unlike rheumatoid
arthritis, development of biologics to treat LN has been
challenging, partially owing to its disease heterogeneity [5].
Thus, unmet needs remain for patients with LN who are
refractory to conventional remission-induction therapy.
Although abnormalities in acquired immunity, such as
the presence of autoreactive T and B cells and autoanti-
bodies, are considered a hallmark of SLE, recent studies
have also highlighted the critical roles of innate immunity,
including macrophages (Mϕ), in SLE. It has been shown
that Mϕ are abundantly present in LN glomerulus and
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that the number of glomerular Mϕ positively correlates
with proteinuria level [6]. Moreover, depletion of Mϕ
ameliorated antibody-induced LN in a nephritis model
[7]. Recently, the novel concept of Mϕ subsets emerged,
comprising proinflammatory, classically activated M1 Mϕ
and anti-inflammatory, alternatively activated M2 Mϕ [8].
The balance between M1 and M2 Mϕ has been implicated
in the pathogenesis of nephritis [9]. In an adriamycin-
induced nephritis model, IL-10/transforming growth
factor-β-modified M2 Mϕ adequately protected against
renal injury [9]. In renal biopsy specimens from patients
with LN, M2c Mϕ (CD68+/CD163+) predominates over
M1 Mϕ (CD68+/inducible nitric oxide synthase-positive)
[10]. Collectively, these data suggest potential roles of M2
Mϕ in LN.
M2 Mϕ highly express CD163, a scavenger receptor of
hemoglobin-derived heme that is widely accepted as one
of the surface markers for M2 Mϕ [11, 12]. Also, phos-
phorylated signal transducer and activator of transcrip-
tion 1 (pSTAT1) and CMAF have been proposed as M1
and M2 Mϕ markers [13]. Haptoglobin-bound heme
captured by CD163 is engulfed into Mϕ lysosomes and
degraded into biliverdin and Fe2+ by inducible enzyme
heme oxygenase (HO)-1. Among the leukocytes, HO-1
is expressed mainly in monocytes/Mϕ lineage cells [14].
Expression of HO-1 is tightly controlled by the tran-
scriptional balance between activator nuclear factor
erythroid 2-related factor 2 (Nrf2) and repressor BTB
and CNC homology 1 (Bach1) [15, 16]. We and others
have previously shown that HO-1 has anti-inflammatory
effects and that its induction is beneficial for the treat-
ment of various inflammatory animal models [17]. We
previously reported that peritoneal injection of hemin, a
chemical inducer of HO-1, into lupus-prone MRL/lpr
mice suppressed proteinuria and kidney injury [18]. In
line with our findings, Nrf2-deficient mice developed
lupus-like autoimmune nephritis [19], whereas treat-
ment with Nrf2 activator dimethyl fumarate ameliorated
pristane-induced LN [20]. These results reinforce the
notion that induction of HO-1 could be beneficial for
the treatment of LN. However, it is still unclear whether
M2 Mϕ play a pathological role in human LN or
whether induction of HO-1 is useful for the treatment of
patients with LN.
In the present study, we demonstrate that M2-like Mϕ
lacking HO-1 expression are found in LN kidneys. Supple-
mentation of HO-1 by targeting Bach1 genes ameliorated
LN in mice, suggesting that dysregulated HO-1low M2 Mϕ
contribute to augmenting the inflammation of LN.
Methods
Patients
All of the patients fulfilled the revised 1997 American
College of Rheumatology criteria for the classification
of systemic lupus erythematosus [21]. Patients enrolled in
the study signed a written informed consent form that
was approved by ethics committee of Yokohama City Uni-
versity Hospital (B130905030).
Mice
MRL/MpJ JmsSlc-lpr/lpr (MRL/lpr) mice were obtained
from Japan SLC (Hamamatsu, Japan). The Bach1−/−
mice (on the C57BL/6J background) used in this study
have been described previously [22]. We obtained
congenic mice by backcrossing with Bach1−/− C57/BL6J
for 12 generations. Male Bach1+/− and female Bach1+/+
MRL/lpr mice were interbred. Mice were genotyped by
PCR using primers previously described [23]. Bach1−/−
MRL/lpr female mice and Bach1+/+ MRL/lpr female
mice were used in this study. Animals were maintained
under specific pathogen-free conditions within the ani-
mal facility at Yokohama City University. Animal treat-
ment protocols were approved by the Yokohama City
University animal protocol ethics committee.
Urine was collected for 6 h from individual 24-week-old
mice in metabolic cages (Shinano Manufacturing Co.,
Tokyo, Japan). Urine protein and creatinine concentra-
tions were determined by using DC Protein Assay Reagent
(Bio-Rad Laboratories, Hercules, CA, USA) and the Par-
ameter Creatinine assay kit (R&D Systems, Minneapolis,
MN, USA). Sera were collected from the tails of 20-week-
old mice. Serum anti-double-stranded DNA (anti-dsDNA)
antibody (immunoglobulin G [IgG]) and blood urea nitro-
gen (BUN) were measured using an enzyme-linked im-
munosorbent assay (Shibayagi, Shibukawa, Japan) [18] and
a BUN colorimetric detection kit (Arbor Assays, Ann
Arbor, MI, USA).
Mϕ from MRL/lpr mice were collected by peritoneal lav-
age with ice-cold PBS. These cells underwent positive selec-
tion by using a CD11b+ MACS antibody (Miltenyi Biotec,
Bergisch Gladbach, Germany), followed by incubation at
37 °C for 40 minutes to remove floating cells [24].
In vitro polarization of human M1- and M2-like Mϕ
Human peripheral blood mononuclear cells were obtained
from heparinized peripheral blood by gradient density
centrifugation using Ficoll-Paque medium. Monocytes
were purified by nonmonocyte depletion with antibody-
conjugated magnetic-activated cell sorting microbeads
(MACS II Monocyte Isolation Kit; Miltenyi Biotec). Cells
were cultured in RPMI 1640 medium (Sigma-Aldrich, St.
Louis, MO, USA) supplemented with 10% FBS (2917354;
MP Biomedicals, Santa Ana, CA, USA), 50 mg/ml strepto-
mycin, and 50 U/ml penicillin. To differentiate cells into
M2- or M1-like Mϕ, 50 ng/ml macrophage colony-
stimulating factor (M-CSF) (216-MC; R&D Systems) or
20 ng/ml granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF) (215-GM; R&D Systems) was added,
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respectively [25]. Cells were incubated for 10 consecutive
days, and medium change was performed at days 2, 5, and
8. For some experiments, M1- and M2-like Mϕ were
stimulated with lipopolysaccharide (LPS) (1 μg/ml, sero-
type 0111:B4; InvivoGen, San Diego, CA, USA), interferon
(IFN)-α2b (1 U/μl; PBL Assay Science, Piscataway, NJ,
USA), or IFN-β (1 U/μl; PBL Assay Science).
Immunohistochemical analysis
Paraffinized renal biopsy specimens were preserved at
Yokohama City University Hospital. Renal pathological
findings were evaluated by the pathologists in accordance
with the International Society of Nephrology/Renal
Pathology Society (ISN/RPS) 2003 classification of LN
[26]. Renal biopsy specimens were sectioned at 3-μm
thickness, deparaffinized in xylene, hydrated in ethanol,
and pretreated with citrate buffer (10 mM sodium cit-
rate, pH 6.0). Slides were autoclaved for 20 minutes,
followed by a 30-minute incubation at room temperature.
Endogenous peroxidase activity was disrupted with 0.3%
H2O2 in methanol for 30 minutes. Immunohistochemistry
was performed on consecutive sections using the follow-
ing antibodies (Abs): CD68 (PGM1) (1:100 dilution,
M0876; Dako/Agilent Technologies, Santa Clara, CA,
USA), CD163 (1:200 dilution, UKNDL-L-CD163; Novocastra
Laboratories, Newcastle, UK), HO-1 (1:500 dilution, ADI-
OSA-110; Enzo Biochem, Farmingdale, NY, USA), and
pSTAT1 (1:400 dilution, D3B7; Cell Signaling Technology,
Danvers, MA, USA), and CMAF (1:50 dilution, M-153,
Santa Cruz Biotechnology, Dallas, TX, USA). Abs were ap-
plied for 60 minutes at 25 °C. Slides were developed using
the Dako EnVision kit (Agilent Technologies). After
hematoxylin staining, total numbers of CD68+, CD163+,
pSTAT1+, CMAF+, and HO-1+ cells within the glomeruli
and representative ex-glomerular lesions were counted. The
number of M1-like Mϕ and M2-like Mϕ were calculated
using the following formula: < CD163 × pSTAT1/(pSTAT1
+ CMAF) > and <CD163 × CMAF/(pSTAT1 + CMAF) >,
where “CD163 × pSTAT1” refers to cells that are double
expressors of CD163 and pSTAT1 and “CD163 × CMAF”
refers to cells that are double expressors of CD163 and
CMAF. For immunocytochemistry, cells incubated on cham-
ber slides were fixed with 4% paraformaldehyde for 10 mi-
nutes, followed by application of the Abs and protocols used
in the aforementioned immunohistochemical analysis. In im-
munofluorescence staining, blocking was performed for 1 h
by 1% Tris-buffered saline (TBS)-4% goat serum-TBS. Stain-
ing was achieved using primary Ab (CD163, pSTAT1, and
CMAF) for 45 minutes at room temperature as described
above. We used Alexa Fluor 555 antimouse IgG (A21425, di-
lution 1:500; Thermo Fisher Scientific, Waltham, MA, USA)
and Alexa Fluor 488 antirabbit IgG (A11034, dilution 1:500;
Thermo Fisher Scientific) as a second antibody.
RT-PCR
Total RNA was extracted using the RNeasy Mini Kit
(Qiagen, Hilden, Germany), and complementary DNA was
prepared with Invitrogen SuperScript II enzyme (Life Tech-
nologies, Carlsbad, CA, USA), according to the manufac-
turers’ protocols. Primers and probes for human and mouse
Hmox1 (Hs00157965_m1, Mm00516004_m1), CD163
(Hs00174705_m1, Mm00474091_m1), Bach1 (Hs00230917_
m1), IL-6 (Hs00174131_m1), IL-10 (Hs00961622_m1), and
Gapdh (4326317E, Mm99999915_g1) for RT-PCR were pur-
chased from Applied Biosystems (Foster City, CA, USA).
Primers for Ifnα and hypoxanthine phosphoribosyltransferase
(Hprt) are listed in Additional file 1: Table S1. RT-PCR was
performed using TaqMan Fast Advanced Master Mix
(Applied Biosystems) or SYBR Green (Fast SYBR Green
Master Mix; Applied Biosystems), and the data were ana-
lyzed with the StepOnePlus Real-Time PCR System (Applied
Biosystems). The data were standardized to the expression of
Gapdh or Hprt. The comparative cycle threshold method
was used to semiquantify messenger RNA (mRNA) levels.
Western blot analysis
Kidney and spleen samples were lysed in lysis buffer (150
mM NaCl, 50 mM 4-[2-hydroxyethyl]-1-piperazineethane-
sulfonic acid, 1 mM ethylenediaminetetraacetic acid, 1%
Triton X-100) in the presence of a protease inhibitor (Roche,
Mannheim, Germany). After 10-minute incubation, cell
membranes were disrupted by ultrasonication (Emerson
Electric, St. Louis, MO, USA). Supernatants were collected
after centrifugation at 15,000 rpm for 30 minutes and ad-
justed to an appropriate concentration with LDS sample
buffer (Life Technologies) and 2-mercaptoethanol
(Sigma-Aldrich). Each lysate was resolved by NuPAGE
4–12% Bis-Tris gel electrophoresis (Life Technologies)
and transferred onto polyvinylidene fluoride (PVDF)
membrane (Merck Millipore, Darmstadt, Germany).
After blocking with 5% skim milk PBS, the PVDF
membrane was probed with antimouse HO-1 mono-
clonal antibody (1:500 dilution) or antimouse Bach1
monoclonal antibody (1:100 dilution, F-9; Santa Cruz
Biotechnology) overnight at 4 °C, followed by incuba-
tion with ECL antimouse IgG horseradish peroxidase-
linked whole antibody (1:5000 dilution; GE Healthcare
Life Sciences, Little Chalfont, UK) for 60 minutes at
room temperature. Blots were developed using ECL
Prime Western Blotting Detection Reagent (GE
Healthcare Life Sciences) and exposed to the LAS-
3000 Mini Imaging System (FUJIFILM, Tokyo, Japan)
for 1–5 minutes.
Statistical analysis
Statistical analysis was performed by using Prism soft-
ware (GraphPad Software, La Jolla, CA, USA). Data are
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presented as mean and SEM. p < 0.05 was considered
statistically significant.
Results
Characteristics of M2-like Mϕ in glomeruli of patients
with LN
In this study, we enrolled 19 patients with LN, including
13 patients with LN newly diagnosed via renal biopsy
(Table 1). The histopathological diagnosis of LN was
made by light microscopy and a routine set of immuno-
fluorescence studies. According to ISN/RPS classifica-
tion, 18 of the 19 patients were categorized into class III
or class IV, and pure class V was found in the remaining
patient (Table 1). Five patients with LN classes I and II
were also evaluated.
Expression of CD68, CD163, HO-1, pSTAT1, CMAF,
and HO-1 was determined in the renal biopsy specimens
using immunohistochemistry. Representative immuno-
histochemical data from a patient with LN (ISN/RPS
class IV-G [A/C]) are shown in Fig. 1a–e. Average cell
numbers of CD68, CD163, and HO-1 per glomerulus in
the renal tissues from the patients with LN were 9.52, 7.95,
and 1.78, respectively (Fig. 1f). We found that numbers of
CD163+ cells were comparable to numbers of CD68+ cells
in the glomerulus of LN. We also found that the number of
CMAF+ M2-like cells was greater than that of pSTAT1+
M1-like cells in the glomerulus of LN (Fig. 1g). Average cell
numbers of M1-like Mϕ, M2-like Mϕ, and HO-1 per glom-
erulus of patients with LN were 1.62, 6.33, and 1.78, re-
spectively (Fig. 1h). Double-immunofluorescence staining
in a representative case indicated that CD163+CMAF+ M2-
like Mϕ are dominant compared with CD163+pSTAT1+
cells in the glomeruli of LN (Fig. 1i, j). Numbers of M2-like
Mϕ per glomeruli positively correlated with urine protein
levels (Fig. 1k), consistent with a previous report [6]. The
number of Mϕ in glomerulus were few in LN classes I
and II (Additional file 1: Figure S1). In extraglomerular
lesions, of LN classes III, IV, and V, the number of M2-
like Mϕ was greater than M1-like Mϕ. Also, HO-1+ cells
were significantly fewer than numbers of M2-like Mϕ
(Additional file 1: Figure S2).
Previous reports have shown that HO-1 mediates the anti-
inflammatory property of M2 Mϕ [27–29]. Nevertheless, the
numbers of HO-1+ cells were fewer than those of M2-like
Mϕ. These data suggest that HO-1 expression is downregu-
lated in glomerular Mϕ of human LN in spite of the M2-like
property.
HO-1 expression is high but is repressed by type I
interferons in human M2-like Mϕ generated in vitro
HO-1 is an inducible protein, and the expression is posi-
tively and negatively modulated by external environ-
ments [27]. We hypothesized that local inflammatory
conditions of LN are responsible for the discrepancy be-
tween CD163/CMAF positivity and HO-1 expression in
glomerular Mϕ. In the present study, we focused on ef-
fects of IFN-α on mRNA expression of both molecules
in human monocyte-derived M2-like Mϕ generated in
vitro, because type I IFN and the related genes are up-
regulated in patients with LN, including the renal tissues
as a so-called IFN signature [1, 3, 30].
Concordant with previous reports [11, 12, 28], our
results confirmed that both CD163 and HO-1 mRNA
and protein expression was high in M2-like Mϕ compared
with M1-like Mϕ in our in vitro culture systems (Fig. 2a, b,
g–l). The in vitro M2-like polarization was associated with
increased mRNA of IL-10, another hallmark of M2 Mϕ,
Table 1 Clinical features of patients with lupus nephritis at
renal biopsy
Characteristics of all patients with SLE
(n = 19)
Data
Female sex, n (%) 15 (78.9)
Age, years 31.0 ± 10.9
Duration of SLE, years 6.1 ± 7.6
Duration of LN, years 2.8 ± 5.8
Initial diagnosis of LN at renal biopsy, n (%) 13 (68.4)
ISN/RPS classification, n
III (A) 4
(A/C) 6 (3)a
IV-S (A) 0
(A/C) 3 (1)a
-G (A) 2
(A/C) 3
V 1
SLEDAI score 16.0 ± 8.9
PSL, n (%) 12 (63.2)
Dosage of PSL, mg/day 15.0 ± 12.4
Concomitant immunosuppressantsb, n (%) 4 (21.1)
Urine protein, g/24 h 1.88 ± 1.93
Serum C3, mg/dl 60.1 ± 22.7 (normal range
70–129)
Serum C4, mg/dl 10.6 ± 6.9 (normal range
12–36)
Serum creatinine, mg/dl 0.65 ± 0.18 (normal range
0.48–0.82)
Anti-DNA- or anti-dsDNA
antibody-positivec, n (%)
17 (89.4)
Abbreviations: dsDNA Double-stranded DNA, ISN/RPS International Society of
Nephrology/Renal Pathology Society, LN Lupus nephritis, SLE Systemic lupus
erythematosus, SLEDAI SLE Disease Activity Index, PSL Prednisolone, C3
Complement component C3, C4 Complement component C4
Data are shown as number (%) or mean ± SD
aNumbers in parentheses show number of patients with class V component
bConcomitant immunosuppressants included mycophenolate mofetil,
cyclophosphamide, azathioprine, and tacrolimus
cAnti-DNA and anti-dsDNA antibody were determined by radioimmunoassay
and enzyme-linked immunosorbent assay, respectively
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whereas that of IL-6 was comparable between M1- and M2-
like Mϕ (Fig. 2c, d). The established M2-like Mϕ were fur-
ther treated with type I IFNs for 4 h. The results showed
that HO-1 expression was suppressed by IFN-α in M2-
like Mϕ (Fig. 2b, k, and l) [14, 31], whereas mRNA of
Bach1, an HO-1 transcriptional repressor, was upregulated
(Fig. 2e). Simultaneously, IL-6 mRNA levels, but not IL-10
levels, were upregulated by IFN-α. The findings were also
found in M2-like Mϕ treated with either IFN-β or LPS
(Additional file 1: Figure S3A). Moreover, the same results
were reproduced in M2-like Mϕ derived from patients
with SLE (Fig. 2f). The results suggest that the type I IFN-
enriched condition in the glomerular lesions of LN sup-
presses HO-1 expression through upregulated Bach1 and
modulates anti-inflammatory properties in M2-like Mϕ.
HO-1 upregulation by genetic ablation of Bach1
ameliorates LN in mice
We and others have reported that induction of HO-1 ex-
pression is beneficial in the treatment of LN [18, 19]. Our
in vitro experiments suggest the involvement of Bach1 in
IFN-α-dependent reduction of HO-1 expression in LN.
To determine the role of Bach1 in the development of LN,
we generated LN-prone MRL/lpr mice lacking Bach1 and
asked whether recovery of HO-1 expression in M2 Mϕ by
Bach1 deficiency leads to amelioration of LN.
Microsatellite analysis (ICLAS Monitoring Center, Kawasaki,
Japan) confirmed the genetic purity of Bach1−/− MRL/MpJ
JmsSlc-lpr/lpr was >99.4% compared with wild type (Additional
file 1: Figure S4). PCR analysis confirmed Bach1 deficiency in
these congenic mice (Additional file 1: Figure S5). Using
Fig. 1 Numbers of CD68+, CD163+, and heme oxygenase (HO)-1+ cells in the glomerulus of patients with lupus nephritis. Representative
immunohistochemical images of the renal biopsy specimen obtained from a patient with lupus nephritis (International Society of Nephrology/
Renal Pathology Society [ISN/RPS] class IV-G [A/C]) are shown. Serial sections of a glomerulus stained with antibodies against (a) CD68, (b) CD163,
(c) HO-1, (d) phosphorylated signal transducer and activator of transcription 1 (pSTAT1), and (e) CMAF (original magnification × 400). f Numbers of
CD68+, CD163+, and HO-1+ cells in glomerulus of renal tissue from patients with systemic lupus erythematosus (SLE) (n = 19) were counted. Data
shown are mean ± SEM. g Numbers of pSTAT1+ and CMAF+ cells in a glomerulus of renal tissue from patients with SLE (n = 19) were counted. h
Numbers of estimated M1 macrophage (Mϕ), M2 Mϕ, and HO-1+ cells in glomerulus in the renal tissues from patients with SLE (n = 19). Data
shown are mean ± SEM. i and j Representative immunofluorescently stained images of the renal biopsy specimen from a patient with lupus
nephritis (ISN/RPS class IV-G [A/C]). Red shows CD163; green shows pSTAT1 (i) or CMAF (j). Double-positive cells indicate M1-like Mϕ and M2-like
Mϕ in (i) and (j), respectively. k Correlation between proteinuria levels (g/day) and numbers of M2-like Mϕ within the glomeruli (n = 19).
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by Student’s t test
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female mice, we observed their phenotypic changes,
including renal function, over the time course. As shown in
Fig. 3a, the survival rate of Bach1−/− MRL/lpr mice was
better than that of Bach1+/+ MRL/lpr mice. Urine total
protein/creatinine ratio at 24 weeks and serum BUN at 20
weeks were decreased in Bach1−/− mice compared with
Bach1+/+ mice (Fig. 3b, c), though there was no difference in
anti-dsDNA Ab(IgG) between the mice (Fig. 3d). The
discrepancy between proteinuria/serum BUN and the sero-
logical findings suggest that Bach1 gene targeting modulates
the innate immune process after immune complex (IC)
deposition, resulting in favorable clinical outcomes of
Bach1−/− MRL/lpr mice. Therefore, we further focused on
the analysis of the renal lesions (Fig. 4a–j).
Immunoblot analysis confirmed the deficiency of Bach1
and increased expression of the HO-1 protein in the kidneys
and spleens of Bach1−/− compared with Bach1+/+ MRL/lpr
mice (Fig. 3e). Concordantly, immunohistochemical analysis
revealed more HO-1-expressing cells in glomeruli from
Bach1−/− mice than in those from Bach1+/+ MRL/lpr mice,
whereas no differences were found in CD68- or CD163-
expressing cells (Fig. 4c, h, and k). However, M2-like
polarization was more prominent in glomerular Mϕ of
Bach1−/− MRL/lpr mice than in the wild-type mice, as
shown by the increased ratio of CD163+ cells per CD68+
cells (Fig. 4l). CMAF+ cells were much more numerous
than pSTAT1+ cells in both Bach1+/+ and Bach1−/− mice
(Fig. 4m, n). The estimated number of M2-like Mϕ was
greater than M1 Mϕ in both Bach1+/+ and Bach1−/− mice.
However, numbers of HO-1+ cells in glomeruli were
greater in Bach1−/− mice (Fig. 4o). PCR analysis also
revealed higher CD163 and HO-1 mRNA expression in
Fig. 2 Expression of CD163, heme oxygenase (HO-1), and BTB and CNC homology 1 (Bach1) in human monocyte-derived M1- and M2-like
macrophages (Mϕ) from healthy donors (HD). Purified peripheral monocytes were cultured in the presence of granulocyte-macrophage colony-
stimulating factor or macrophage colony-stimulating factor for 10 days to induce differentiation of M1- or M2-like Mϕ, respectively. Messenger
RNA (mRNA) expression was semiquantitatively determined from M1- and M2-like Mϕ generated from HD in vitro (n = 6) by RT-PCR of (a) CD163,
(b) HO-1, (c) interleukin (IL)-10, (d) IL-6, and (e) Bach1. f HO-1 mRNA expression of M1- and M2-like Mϕ from patients with systemic lupus
erythematosus (SLE) stimulated with interferon (IFN)-α (n = 6). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 by Student’s t test. Data shown
are mean ± SEM. Representative immunocytochemical staining shows results for M1- and M2-like Mϕ stimulated with or without human recombinant IFN-α.
CD163 (g–i) and HO-1 (j–l) (original magnification × 400). RQ Relative quantification
Kishimoto et al. Arthritis Research & Therapy  (2018) 20:64 Page 6 of 11
the kidneys of Bach1−/− mice than in wild-type mice,
whereas the IFN-α expression level was rather decreased
in Bach1−/− MRL/lpr mice (Fig. 4p–r).
To further compare the characteristics of Mϕ in these
mice, Mϕ obtained from peritoneal lavage were exam-
ined (Fig. 4s, t). We found that Mϕ from Bach1−/−
MRL/lpr mice expressed higher levels of CD163 and
HO-1 mRNA than wild-type mice did, suggesting that
M2-like polarization is more evident in Bach1 deficiency,
consistent with the results of a previous paper [24].
Collectively, these data suggest that Bach1 negatively reg-
ulates HO-1 expression and M2 Mϕ polarization, leading
to the inflammation of LN.
Discussion
In the present study, we showed high numbers of M2-like
Mϕ than M1-like Mϕ within the glomerulus of patients with
LN, suggesting an M2 shift in LN. However, HO-1 expres-
sion was reduced in these abundantly present M2-like Mϕ
(Fig. 1). Moreover, human monocyte-derived M2-like Mϕ
treated with type I IFNs showed reduced HO-1 and in-
creased Bach1 expression. Mϕ from Bach1-deficient mice
showed an M2 shift along with high HO-1 expression, con-
sistent with a previous report [24]. These data suggest that
HO-1-expressing M2 Mϕ are necessary to regulate LN.
Over the past few decades, authors of hundreds of pa-
pers have reported the anti-inflammatory properties of
HO-1 in various inflammation settings. Indeed, HO-1
deficiency in humans and mice exhibits marked inflam-
mation caused by oxidative stress [32, 33]. Moreover, we
previously reported that HO-1 knockdown by small
interfering RNA resulted in an enhanced inflammatory
response in human monocytes [14]. Therefore, it is likely
that these “HO-1-deficient M2-like Mϕ” in LN are pro-
inflammatory rather than anti-inflammatory as in ordin-
ary M2 Mϕ. Indeed, the results of the present study
show low HO-1 and high IL-6 production in human M2
Mϕ stimulated with IFN-α (Fig. 2b and d). Besides, a
previous study demonstrated that chemical induction of
HO-1 was beneficial in the LN murine model [18].
Along the same line, the present study provides hope
that the cell population could be reversed into anti-
inflammatory M2 Mϕ through induction of HO-1 via in-
hibition of Bach1.
Fig. 3 Phenotypic analysis of BTB and CNC homology 1 (Bach1)-deficient MRL/lpr mice. Clinical and renal findings were compared between
Bach1+/+ and Bach1−/− MRL/lpr mice as follows. a Kaplan-Meier survival analysis. b Proteinuria (g/g*Cr). c Serum blood urea nitrogen (BUN)
(mg/dl) at 24 weeks. d Anti-double-stranded DNA (anti-dsDNA) antibody (Ab) immunoglobulin G (IgG) (U/ml). *p < 0.05 by Student’s t test. n.s.
Not significant. Data shown are mean ± SEM. e Immunoblot analysis of Bach1, heme oxygenase (HO)-1, and glyceraldehyde 3-phosphate
dehydrogenase (Gapdh) in whole spleens and kidneys
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LN is considered a representative IC disease caused by
anti-dsDNA Ab IC deposition in the glomerulus. Subse-
quently, the deposited IC triggers activation of the com-
plement system and preferentially promotes M2 Mϕ
polarization [34]. Our data show that anti-inflammatory
properties of glomerular M2 Mϕ are abrogated by a sys-
temic and local IFN signature that suppresses HO-1
through upregulation of Bach1. Moreover, costimulation
with Toll-like receptor ligands, which reduced HO-1 ex-
pression in this study, and IgG promotes inflammatory
responses of M2 Mϕ instead of suppressing inflamma-
tion via Fcγ receptor IIa [35]. Our in vitro analysis
suggests that the functional changes of M2-like Mϕ are
associated with an altered cytokine profile characterized
by increased IL-6 synthesis while maintaining IL-10 pro-
duction capacity (Fig. 2). Both cytokines are implicated
in the pathogenesis of SLE, because recent genetic
studies have identified the IL10 risk allele in SLE [36].
Our hypothesis proposed on the basis of this study is
summarized in Fig. 5. Collectively, M2 Mϕ dysfunction
may facilitate the inflammation in LN. Bach1-mediated
HO-1 supplementation is one of the promising strategies
to “tame” these aberrantly activated M2 Mϕ in LN.
In the present study, we demonstrate that Bach1 is in-
duced by type I IFNs in human M2-like Mϕ (Fig. 2e).
Elucidating the mechanisms of how type I IFNs regulate
Bach1 expression is essential. Bach1 was initially identi-
fied as a Maf-binding protein, and it now is well estab-
lished that Bach1 forms a heterodimer with small Maf
[37]. A recent study showed that MafB is involved in the
regulation of IRF3-dependent type I IFN-inducible genes
[38]. Interestingly, genome-wide association studies
(GWAS) identified Bach2, which belongs to the same
family as Bach1, as being associated with SLE [39].
Fig. 4 Characteristics of cells within the glomeruli of BTB and CNC homology 1 (Bach1)-deficient MRL/lpr mice. Immunohistochemical staining of
the renal tissues for CD68 (a, f), CD163 (b, g), heme oxygenase (HO)-1 (c, h), phosphorylated signal transducer and activator of transcription 1
(pSTAT1) (d, i), and CMAF (e, j) (original magnification × 400). k Numbers of CD68+, CD163+, and HO-1+ cells in glomeruli of mice. l Ratio of
CD163+ and CD68+ cells within the glomerulus of Bach1+/+ and Bach1−/− MRL/lpr mice. m and n Numbers of pSTAT1+ and CMAF+ cells in
glomeruli of Bach1+/+ and Bach1−/− MRL/lpr mice (n = 2 from each group). o Numbers of estimated M1 macrophage (Mϕ), M2 Mϕ, and HO-1+
cells in glomeruli in the renal tissues from Bach1+/+ and Bach1−/− MRL/lpr mice. Data shown are mean ± SEM. Three glomeruli from each mouse
were evaluated. (p) CD163, (q) HO-1, and (r) interferon (IFN)-α messenger RNA (mRNA) from the whole kidneys. mRNA expression of (s) CD163
and (t) HO-1 of CD11b+ peritoneal Mϕ. *p < 0.05, **p < 0.01, ***p < 0.001 by Student’s t test. Data shown are mean ± SEM
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These findings and our data suggest that Bach1 is critic-
ally involved in type I IFN-mediated inflammation, in-
cluding SLE.
Bach2 regulates antibody class switch in B cells [40],
thus contributing to acquired immunity because it is
identified as a susceptible gene in GWAS of various
autoimmune diseases [39]. In contrast, a primary source
of Bach1 is monocytes (BioGPS GeneAtlas U133A,
gcrma), and Bach1 was identified as one of the core
Mϕ-associated genes in mice [41], suggesting that Bach1
plays a strong role in innate immunity. In this context,
Bach1-deficient mice showed a milder LN phenotype
than wild-type mice without affecting anti-dsDNA anti-
body production (Fig. 3c). This fact suggests that innate
immune responses after IC deposition on glomerulus are
also significant in this model. Although the mainstay of
current treatment strategies for LN is to suppress ac-
quired immunity, including pathogenic autoantibody
production, our data support an alternative treatment
strategy directed against innate immunity via Bach1. The
approach is expected to have an advantage over conven-
tional therapies regarding safety issues, especially for
complications with infection because systemic immuno-
suppressive effects are marginal.
There are several possible strategies to treat LN by target-
ing the Bach1, HO-1, and M2 Mϕ. First, inhibition of
Bach1 transcription is promising. Recently, the novel Bach1
inhibitor HPP971, which increases HO-1 expression, was
developed [42]. Nrf2, a competitor to Bach1, is an alterna-
tive because Nrf2-deficient mice showed a phenotype
resembling LN [43]. Treatment with novel Nrf2 inducer
TFM-735 ameliorated experimental autoimmune enceph-
alomyelitis [44]. Finally, supplementation or generation of
normal HO-1-expressing M2 Mϕ could also be beneficial
for LN. It has been shown that adoptive transplant of M2
Mϕ, but not of M1 Mϕ, reduced SLE severity in clodro-
nate- and activated lymphocyte-derived DNA-treated
mice [45].
Conclusions
Our data suggest that functional alteration of M2 Mϕ
plays an important role in LN and that Bach1 is a thera-
peutic target for LN.
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